{"entity":{"id":"nct04205630","kind":"trial","name":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma","aka":[],"tldr":"A phase 2 trial of Trastuzumab duocarmazine in Endometrial cancer, run by Byondis B.V., completed.","summary":"SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma is a phase 2 interventional study registered as NCT04205630 by Byondis B.V., with 64 participants recorded, started 2020-05-28 and reaching its primary completion in 2023-01-26. Interventions recorded: SYD985. Conditions recorded: Endometrial Cancer.\n\nLinked to the drug Trastuzumab duocarmazine because the registry names it among its interventions and Endometrial cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT04205630","url":"https://clinicaltrials.gov/study/NCT04205630"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","advanced-recurrent-endometrial-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-duocarmazine"],"companies":["byondis"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04205630","phase":"2","setting":"A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy","sponsor":"Byondis B.V.","started":"2020-05-28","startedType":"actual","yearReported":2024,"enrolled":64,"enrolledBasis":"registry","outcomes":[{"endpoint":"Objective Response Rate (ORR)","primary":true,"unit":"participants","arms":[{"name":"SYD985","n":61,"value":20,"note":"Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04205630?tab=results"},{"endpoint":"Overall Survival (OS)","unit":"months","arms":[{"name":"SYD985","n":64,"value":16.3,"note":"95% CI 11.6 to 20.5; Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04205630?tab=results"},{"endpoint":"Progression-Free Survival (PFS)","unit":"months","arms":[{"name":"SYD985","n":64,"value":5.6,"note":"95% CI 4.0 to 7.6; Figures from the ClinicalTrials.gov results section (first posted 2024-05-30), not from a publication"}],"source":"https://clinicaltrials.gov/study/NCT04205630?tab=results"}]},"route":"/trials/nct04205630/","neighbours":{"cancer":[{"id":"advanced-recurrent-endometrial-cancer","kind":"cancer","name":"Advanced or recurrent endometrial cancer","route":"/cancers/advanced-recurrent-endometrial-cancer/"},{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"drug":[{"id":"trastuzumab-duocarmazine","kind":"drug","name":"Trastuzumab duocarmazine","route":"/drugs/trastuzumab-duocarmazine/"}],"company":[{"id":"byondis","kind":"company","name":"Byondis","route":"/companies/byondis/"}]}}